Pyridoxamine: the many virtues of a maillard reaction inhibitor. (Q34436025)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Pyridoxamine: the many virtues of a maillard reaction inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Paul A Voziyan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 June 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

1043

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

807-816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

Vitamin B6 metabolism by human liver

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Advanced protein glycosylation in diabetes and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Role of the Maillard reaction in diabetes mellitus and diseases of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Chelating activity of advanced glycation end-product inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Maillard reaction products in tissue proteins: new products and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Clinical review 32: Calcium oxalate nephrolithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Paradoxical impact of antioxidants on post-Amadori glycoxidation: Counterintuitive increase in the yields of pentosidine and Nepsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

Glycoxidation and lipoxidation in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

The Maillard hypothesis on aging: time to focus on DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

A General Mechanism for Vitamin B6-catalyzed Reactions1

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1333.093

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1333.093

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16037308%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference